A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial transcriptional repressor protein EthR is an...

Full description

Saved in:
Bibliographic Details
Published inOrganic & biomolecular chemistry Vol. 14; no. 7; pp. 2318 - 2326
Main Authors Nikiforov, Petar O., Surade, Sachin, Blaszczyk, Michal, Delorme, Vincent, Brodin, Priscille, Baulard, Alain R., Blundell, Tom L., Abell, Chris
Format Journal Article
LanguageEnglish
Published CAMBRIDGE Royal Soc Chemistry 21.02.2016
Royal Society of Chemistry
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial transcriptional repressor protein EthR is an attractive therapeutic strategy. Herein we report the use of a fragment based drug discovery approach for the structure-guided systematic merging of two fragment molecules, each binding twice to the hydrophobic cavity of EthR from M. tuberculosis. These together fill the entire binding pocket of EthR. We elaborated these fragment hits and developed small molecule inhibitors which have a 100-fold improvement of potency in vitro over the initial fragments.
Bibliography:researchfish
UKRI
PMCID: PMC4759522
ISSN:1477-0520
1477-0539
DOI:10.1039/c5ob02630j